Exelixis
EXEL
#2109
Rank
A$11.30 B
Marketcap
$39.63
Share price
-1.53%
Change (1 day)
18.25%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total liabilities

Total liabilities on the balance sheet as of June 2024 : A$0.98 B

According to Exelixis's latest financial reports the company's total liabilities are A$0.98 B. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Exelixis - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31A$0.99 B16.22%
2022-12-31A$0.85 B53.59%
2021-12-31A$0.55 B66.47%
2020-12-31A$0.33 B17.96%
2019-12-31A$0.28 B48.48%
2018-12-31A$0.19 B-59.67%
2017-12-31A$0.47 B-32.48%
2016-12-31A$0.70 B8.16%
2015-12-31A$0.64 B21.58%
2014-12-31A$0.53 B9.03%
2013-12-31A$0.48 B19.63%
2012-12-31A$0.40 B38.77%
2011-12-31A$0.29 B-49.28%
2010-12-31A$0.58 B2.62%
2009-12-31A$0.56 B-14.47%
2008-12-31A$0.66 B77.37%
2007-12-31A$0.37 B-3.33%
2006-12-31A$0.38 B2.72%
2005-12-31A$0.37 B21.03%
2004-12-31A$0.31 B17.76%
2003-12-31A$0.26 B-8.82%
2002-12-31A$0.28 B35.13%
2001-12-31A$0.21 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
A$84.06 B 8,477.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
A$91.25 B 9,212.05%๐Ÿ‡ซ๐Ÿ‡ท France
A$103.46 B 10,457.60%๐Ÿ‡บ๐Ÿ‡ธ USA
A$116.35 B 11,773.06%๐Ÿ‡บ๐Ÿ‡ธ USA
A$127.46 B 12,906.38%๐Ÿ‡บ๐Ÿ‡ธ USA
A$164.31 B 16,666.48%๐Ÿ‡บ๐Ÿ‡ธ USA
A$192.31 B 19,523.59%๐Ÿ‡บ๐Ÿ‡ธ USA
A$76.65 M-92.18%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.10 B-88.92%๐Ÿ‡บ๐Ÿ‡ธ USA